ANIP Q2 2023 Earnings — ANI Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena

ANIPANI Pharmaceuticals, Inc.

$2B

Q2 2023 Earnings

Healthcare Drug Manufacturers - Specialty & Generic

Income Statement

Revenue

$117M+57.8% YoY

Gross Profit

$74M63.7% margin

Operating Income

$12M10.6% margin

Net Income

$6M5.4% margin

EPS (Diluted)

$0.33

QoQ Revenue Growth

+9.1%

Cash Flow

Operating Cash Flow

$21M

Free Cash Flow

$14M

Stock-Based Comp.

$5M

Balance Sheet

Total Assets

$859M

Total Liabilities

$425M

Stockholders' Equity

$434M

Cash & Equivalents

$162M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$117M	$74M	+57.8%
Gross Profit	$74M	$39M	+92.6%
Operating Income	$12M	-$13M	+196.0%
Net Income	$6M	-$15M	+141.8%

Revenue Segments

Generics, Established Brands, and Other

$92M79%

Rare Disease

$24M21%

Geographic Segments

UNITED STATES

$117M100%